Renin-Angiotensin System-Modifying Antihypertensive Drugs Can Reduce the Risk of Cardiovascular Complications in Lupus: A Retrospective Cohort Study

Overview

Journal Am J Med

Specialty General Medicine

Date 2022 Dec 10

PMID 36495935

Authors

Chelsie Hurst

Maira Soto

Ernest R Vina

Kathleen E Rodgers

Affiliations

Soon will be listed here.

Abstract

Background: Patients with systemic lupus erythematosus have a higher incidence of cardiovascular disease than the general population. Antihypertensive drugs that modify the renin-angiotensin system (RAS) are used to protect renal function in lupus nephritis and may also have extrarenal effects that lower cardiovascular disease risk due to their anti-inflammatory properties. In this study, we compared the effects of RAS vs non-RAS antihypertensive drugs on cardiovascular disease incidence in patients with lupus.

Methods: Using a medical insurance claims dataset, 220,168 patients with lupus were identified, of which 31,647 patients (4018 patients prescribed RAS drugs, 27,629 patients prescribed non-RAS drugs) were eligible for the study. Patients had a mean age of 46.1 years, were 93.0% female, and healthy (96.9% Charlson Comorbidity Index score 0-4). Patients in the 2 drug groups were propensity score matched using demographic data, risk factors, and comorbidities.

Results: Use of RAS vs non-RAS drugs lowered the relative risk (RR) of diagnosis of cardiovascular disease (RR 0.80; 95% confidence interval [CI], 0.74-0.87), which was more pronounced after propensity score matching (RR 0.62; 95% CI, 0.57-0.68). The decreased risk in cardiovascular disease occurred regardless of lupus nephritis status (with lupus nephritis: RR 0.51; 95% CI, 0.39-0.65; without lupus nephritis: RR 0.65; 95% CI, 0.59-0.72). RAS-modifying therapies significantly increased cardiovascular disease-free survival probability over a 5-year period (86.0% vs 78.3% probability).

Conclusions: RAS-modifying drugs reduced the risk of cardiovascular disease in patients with systemic lupus erythematosus in this dataset. These findings have the potential to impact clinical decision-making with regards to hypertension management in patients with lupus.

Citing Articles

Causal relationship between antihypertensive drugs and Hashimoto's thyroiditis: a drug-target Mendelian randomization study.

Cui B, Chen A, Xu C, Mao C, Chen Y Front Endocrinol (Lausanne). 2024; 15:1419346.

PMID: 39435355 PMC: 11491371. DOI: 10.3389/fendo.2024.1419346.

Increased carotid intima-media thickening and antioxidized low-density lipoprotein in an anti-Ro60 SLE autoantibody subset.

Kurien B, Fesmire J, Nath S, Scofield R Front Lupus. 2024; 1.

PMID: 39055110 PMC: 11270588. DOI: 10.3389/flupu.2023.1197309.

References

Cojocaru M, Cojocaru I, Silosi I, Vrabie C . Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2012; 6(4):330-6. PMC: 3391953. View

Zeller C, Appenzeller S . Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors. Curr Cardiol Rev. 2009; 4(2):116-22. PMC: 2779351. DOI: 10.2174/157340308784245775. View

Yu H, Chen P, Yang Y, Wang L, Lee J, Lin Y . Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study. Atherosclerosis. 2015; 243(1):11-8. DOI: 10.1016/j.atherosclerosis.2015.08.030. View

Kim C, Al-Kindi S, Jandali B, Askari A, Zacharias M, Oliveira G . Incidence and risk of heart failure in systemic lupus erythematosus. Heart. 2016; 103(3):227-233. DOI: 10.1136/heartjnl-2016-309561. View

Hsu C, Lin M, Su Y, Cheng T, Lin Y, Chen Y . Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford). 2017; 56(4):620-628. DOI: 10.1093/rheumatology/kew457. View

Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman D, Urowitz M . The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010; 62(3):863-8. DOI: 10.1002/art.27289. View

Austin P . An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011; 46(3):399-424. PMC: 3144483. DOI: 10.1080/00273171.2011.568786. View

Ranjbar R, Shafiee M, Hesari A, Ferns G, Ghasemi F, Avan A . The potential therapeutic use of renin-angiotensin system inhibitors in the treatment of inflammatory diseases. J Cell Physiol. 2018; 234(3):2277-2295. DOI: 10.1002/jcp.27205. View

Perez De Lema G, De Wit C, Cohen C, Nieto E, Molina A, Banas B . Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice. J Pharmacol Exp Ther. 2003; 307(1):275-81. DOI: 10.1124/jpet.103.053678. View

10.

Barnado A, Casey C, Carroll R, Wheless L, Denny J, Crofford L . Developing Electronic Health Record Algorithms That Accurately Identify Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2016; 69(5):687-693. PMC: 5219863. DOI: 10.1002/acr.22989. View

11.

McMahon M, Hahn B, Skaggs B . Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol. 2011; 7(2):227-41. PMC: 3718673. DOI: 10.1586/eci.10.98. View

12.

Ettehad D, Emdin C, Kiran A, Anderson S, Callender T, Emberson J . Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022):957-967. DOI: 10.1016/S0140-6736(15)01225-8. View

13.

Tektonidou M, Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis P, Protogerou A . Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis. Autoimmun Rev. 2017; 16(3):308-312. DOI: 10.1016/j.autrev.2017.01.009. View

14.

Lavoie J, Sigmund C . Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system. Endocrinology. 2003; 144(6):2179-83. DOI: 10.1210/en.2003-0150. View

15.

Chen Y, Li L, Tang W, Song J, Qiu R, Li Q . First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2018; 11:CD008170. PMC: 6516995. DOI: 10.1002/14651858.CD008170.pub3. View

16.

Fanouriakis A, Kostopoulou M, Cheema K, Anders H, Aringer M, Bajema I . 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020; 79(6):713-723. DOI: 10.1136/annrheumdis-2020-216924. View

17.

Sparks M, Crowley S, Gurley S, Mirotsou M, Coffman T . Classical Renin-Angiotensin system in kidney physiology. Compr Physiol. 2014; 4(3):1201-28. PMC: 4137912. DOI: 10.1002/cphy.c130040. View

18.

Thomopoulos C, Parati G, Zanchetti A . Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens. 2018; 36(8):1637-1647. DOI: 10.1097/HJH.0000000000001777. View

19.

Fernandez-Nebro A, Rua-Figueroa I, Lopez-Longo F, Galindo-Izquierdo M, Calvo-Alen J, Olive-Marques A . Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry. Medicine (Baltimore). 2015; 94(29):e1183. PMC: 4603000. DOI: 10.1097/MD.0000000000001183. View

20.

Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A . Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol. 2004; 31(4):713-9. View